{
  "docId": "019de070-3a76-76eb-bdcd-70a194f2629a",
  "docSlug": "3b5651eafaa236908b5aaeea5fdc2dcc",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 28,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a process flow diagram to illustrate the clinical trial phases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-3a76-76eb-bdcd-70a194f2629a/13",
  "deckHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a",
  "deckJsonHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a.json",
  "deckAnchorHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.55,
        "x": 0.4,
        "y": 0.3
      },
      "kind": "diagram",
      "text": "Trial flow diagram showing patient screening, randomization (R 2:1), treatment arms (Pegzilarginase vs Placebo), and open-label extension over time.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d528bdf1-785a-4ac1-9de5-a8d369272242",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.04,
        "y": 0.34
      },
      "kind": "list",
      "text": "Primary: plasma arginine reduction\nSecondary: clinical responder endpoint\n- Timed Walk Test (2MWT)\n- GMFM-D (Standing)\n- GMFM-E (Walking, Running & Jumping)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05262a50-3f89-4842-a3e1-9c21f08a5544",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.46,
        "x": 0.43,
        "y": 0.198
      },
      "kind": "paragraph",
      "text": "Single, Global Pivotal Phase 3 Trial Based on Input From FDA and EMA to Support Registration",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "139163dd-5260-4f0b-a957-977829a5e50c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.55,
        "x": 0.4,
        "y": 0.73
      },
      "kind": "source-note",
      "text": "*Dosing is weekly and, if needed, modified based on plasma arginine levels with maintenance of blinding. 'The first 8 weeks of the open-label extension will be blinded. All study participants remain on current disease management for the duration of the trial. ARG1-D = Arginase 1 Deficiency; IV = intravenous; R = randomized.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0028b232-48c0-4a86-b96d-987346d08173",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Pivotal Phase 3: PEACE Trial Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9b7a0fc-1795-4504-8c5b-9c883ab5d7d6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "6da44006-90c4-4f9c-8964-0b56ccc84c11",
      "evidence": "The slide outlines the structure of a Phase 3 clinical trial including randomization, arms, and endpoints.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}